Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses the path of telemedicine reimbursement during the pandemic and possible ways it will change after the pandemic.
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses the path of telemedicine reimbursement during the pandemic and possible ways it will change after the pandemic, including that some aspects of radiation treatment supervision will go away.
Transcript
How would you characterize telemedicine reimbursement in the oncology setting?
So far, reimbursement is going really well for telemedicine. We know that Medicare has put as part of their proposed fee schedule, the Physician Fee Schedule, reimbursement for telemedicine that will be robust. Only some aspects of radiation treatment supervision will go away after the global pandemic. So when Medicare reimbursement is strong, commercial payers tend to follow and we also were observing that. Now, there are state policies that vary by state regarding telemedicine, so each state has to make sure that they curate and advocate for appropriate telemedicine policy at the state level. But I think telemedicine is here to stay in ways that continue to be clinically meaningful to patient care.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Medicare Costs Push Financial Limits of Many Older Adults
October 28th 2024Patients with Medicare coverage and whose incomes fall between 100% and 400% or less of the federal poverty level may find themselves in a tricky financial situation concerning their ability to pay the Medicare Part A hospital deductible.
Read More